Close Window

Digital Look Email A Friend

Angle's Parsortix to be used in 'significant' prostate cancer study

Published by Josh White on 20th May 2022

(Sharecast News) - Liquid biopsy company Angle announced on Friday that Prostate Cancer UK has approved funding for a "significant" clinical study at the Barts Cancer Institute of the Queen Mary University of London.

URL: http://www.digitallook.com/dl/news/story/32693727/...

Email this article to your friends
NOTE: These email addresses will be used to email the information on your behalf and will not be collected by Digital Look for any marketing purposes.